{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:12Z","timestamp":1790679192502,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK76877"],"award-info":[{"award-number":["R01 DK76877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi \u2014 Genzyme (Portugal)","award":["PR11398030"],"award-info":[{"award-number":["PR11398030"]}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"A Sanofi Division (Canada)"},{"name":"Canadian Institutes of Health Research (CIHR)","award":["200709ISO-179883-UI-CFDA-153107"],"award-info":[{"award-number":["200709ISO-179883-UI-CFDA-153107"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.cca.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T02:34:14Z","timestamp":1434162854000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma"],"prefix":"10.1016","volume":"447","author":[{"given":"Susana","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-1967","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2015.06.003_bb0005","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.cca.2015.06.003_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tcm.2007.02.006","article-title":"Alpha-galactosidase A in vascular disease","volume":"17","author":"Bodary","year":"2007","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cca.2015.06.003_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cca.2015.06.003_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","article-title":"Vasculopathy in patients with Fabry disease: current controversies and research directions","volume":"99","author":"Rombach","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: a key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CNP57001","article-title":"Enzyme replacement therapy for Fabry disease, an inherited nephropathy","volume":"57","author":"Desnick","year":"2002","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0045","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2008.02.050","article-title":"Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results","volume":"51","author":"Linthorst","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cca.2015.06.003_bb0050","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1681\/ASN.2008020198","article-title":"X inactivation, female mosaicism, and sex differences in renal diseases","volume":"19","author":"Migeon","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2015.06.003_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2015.06.003_bb0065","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2015.06.003_bb0070","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00019053-200725030-00003","article-title":"Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease","volume":"25","author":"Moore","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.cca.2015.06.003_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1750-1172-8-29","article-title":"Cost-effectiveness of enzyme replacement therapy for Fabry disease","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0080","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cca.2015.06.003_bb0085","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2015.06.003_bb0090","doi-asserted-by":"crossref","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2015.06.003_bb0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","article-title":"The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature","volume":"4","author":"Bekri","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15353\/cjo.74.550","article-title":"Improved ways to screen for patients with Fabry disease, involving optometry in a multidisciplinary approach","volume":"74","author":"Michaud","year":"2012","journal-title":"Can J Optom"},{"key":"10.1016\/j.cca.2015.06.003_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.cca.2015.06.003_bb0125","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2015.06.003_bb0130","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2015.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0150","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0155","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0160","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC\u2013MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0175","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0185","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb\u2083-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0190","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"3","author":"Group KDIGOKCW","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.cca.2015.06.003_bb0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"Suppl. 2","key":"10.1016\/j.cca.2015.06.003_bb0200","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1007\/s10545-008-0972-0","article-title":"The g.1170C>T polymorphism of the 5\u2032 untranslated region of the human alpha-galactosidase gene is associated with decreased enzyme expression\u2014evidence from a family study","volume":"31","author":"Oliveira","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.cca.2015.06.003_bb0215","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.repc.2014.02.021","article-title":"Histopathological evidence of Fabry disease in a female patient with left ventricular noncompaction","volume":"33","author":"Martins","year":"2014","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.cca.2015.06.003_bb0220","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1080\/14764170802275832","article-title":"Angiokeratomas of Fabry successfully treated with intense pulsed light","volume":"10","author":"Morais","year":"2008","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.cca.2015.06.003_bb0225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","article-title":"Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study\u2013screening genetic conditions in Portuguese young stroke patients","volume":"41","author":"Baptista","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2015.06.003_bb0230","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0235","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/jmg.30.8.658","article-title":"Sequence variations in the first exon of alpha-galactosidase A","volume":"30","author":"Davies","year":"1993","journal-title":"J Med Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neulet.2011.05.238","article-title":"Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease","volume":"500","author":"Wu","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.cca.2015.06.003_bb0245","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","article-title":"Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene","volume":"81","author":"Ferri","year":"2012","journal-title":"Clin Genet"},{"issue":"Suppl. 2","key":"10.1016\/j.cca.2015.06.003_bb0250","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1007\/s10545-008-0818-9","article-title":"Effect of single-nucleotide polymorphisms of the 5\u2032 untranslated region of the human alpha-galactosidase gene on enzyme activity, and their frequencies in Portuguese Caucasians","volume":"31","author":"Oliveira","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb(3)\/creatinine biomarkers for Fabry disease: issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0260","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2015.06.003_bb0265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5414\/CN108053","article-title":"Prevalence of Fabry's disease within hemodialysis patients in Spain","volume":"81","author":"Herrera","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0270","doi-asserted-by":"crossref","first-page":"e000394","DOI":"10.1161\/JAHA.113.000394","article-title":"Risk of death in heart disease is associated with elevated urinary globotriaosylceramide","volume":"3","author":"Schiffmann","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cca.2015.06.003_bb0275","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00428-011-1182-y","article-title":"Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections","volume":"460","author":"Valbuena","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cca.2015.06.003_bb0280","first-page":"741","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"2010","author":"Rombach","year":"1802","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0285","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography\u2014tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2015.06.003_bb0290","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2015.06.003_bb0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2015.06.003_bb0300","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0305","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2015.06.003_bb0310","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications","volume":"43","author":"Meehan","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cca.2015.06.003_bb0315","doi-asserted-by":"crossref","first-page":"c33","DOI":"10.1159\/000085709","article-title":"Fabry disease in patients with end-stage renal failure: the potential benefits of screening","volume":"101","author":"Bekri","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.cca.2015.06.003_bb0320","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0330","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3904\/kjim.2010.25.4.415","article-title":"Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea","volume":"25","author":"Kim","year":"2010","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.cca.2015.06.003_bb0335","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/0886022X.2012.669300","article-title":"Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients","volume":"34","author":"Nishino","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.cca.2015.06.003_bb0340","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/jhg.2012.68","article-title":"High-throughput screening identified disease-causing mutants and functional variants of alpha-galactosidase A gene in Japanese male hemodialysis patients","volume":"57","author":"Doi","year":"2012","journal-title":"J Hum Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0345","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2215\/CJN.08780812","article-title":"Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine","volume":"8","author":"Maruyama","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2015.06.003_bb0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","article-title":"Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation","volume":"527","author":"Okur","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.cca.2015.06.003_bb0355","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2015.06.003_bb0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/STROKEAHA.109.558320","article-title":"Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke","volume":"41","author":"Wozniak","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2015.06.003_bb0365","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.cca.2015.06.003_bb0370","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J Am Soc Mass Spectrom"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115002818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898115002818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T17:55:51Z","timestamp":1566842151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898115002818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":74,"alternative-id":["S0009898115002818"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2015.06.003","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}